Skip to main content
European Journal of Hybrid Imaging

EJNMMI Multimodality Journal

Download PDF

18F-FDG-PET/CT in radiation therapy-induced parotid gland inflammation

European Journal of Hybrid Imaging volume 4, Article number: 22 (2020) Cite this article

Abstract

Background

18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is used in the clinical management of oncologic and inflammatory pathologies. It may have utility in detecting radiotherapy (RT)-induced damage of oral tissues. Thus, the aim of the present study was to use FDG-PET/CT to evaluate parotid gland inflammation following RT in patients with head and neck cancer (HNC).

Methods

This retrospective study included patients with HNC treated with photon, proton, or combined photon/proton RT, in addition to chemotherapy. All patients received FDG-PET/CT imaging pre-treatment and 3 months post-treatment. The average mean standardized uptake value (Avg SUVmean) and the average maximum standardized uptake value (Avg SUVmax) of the left and right parotid glands were determined by global assessment of FDG activity using OsiriX MD software. A two-tailed paired t test was used to compare Avg SUVmean and Avg SUVmax pre- and post-RT.

Results

Forty-seven HNC patients were included in the study. Parotid gland Avg SUVmean was significantly higher at 3 months post-treatment than pre-treatment (p < 0.05) in patients treated with photon RT, but no significant differences were found between pre- and post-treatment Avg SUVmean in patients treated with proton RT or combined photon/proton RT.

Conclusion

Our results suggest that photon RT may cause radiation-induced inflammation of the parotid gland, and that proton RT, which distributes less off-target radiation, is a safer treatment alternative.

Background

Head and neck cancers (HNC) represent approximately 4% of all cancers in the USA (Head and Neck Cancer - Statistics, 2012). This group of malignancies affects a variety of anatomic structures, including the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, paranasal sinuses, and salivary glands (Alterio et al., 2019). Along with surgical resection and/or chemotherapy, HNC may be treated with radiation therapy (RT) as either definitive or adjuvant treatment (Alterio et al., 2019).

The majority of radiation treatment modalities for HNC consist of external beam photon therapy, which has been associated with many systemic sequelae including pneumonitis and vasculitis (Giuranno et al., 2019; Chrapko et al., 2016). Oral complications of RT have proven to be very common in cancer patients, especially those with HNC (Chen, 2019). Critical anatomical structures in close proximity to the irradiated area are often affected during treatment resulting in complications including fibrosis, taste changes, dental caries, periodontal disease, and oral mucositis (Alterio et al., 2019; Shunmuga Sundaram et al., 2019). Because these alterations can have adverse effects on the lifestyle and health outcomes of HNC patients, it is critical to establish an understanding of the off-target effects of RT on the oral region, which contains tissues that are particularly susceptible to radiation-induced damage.

The parotid gland is the largest of the salivary glands and produces 60 to 65% of the total saliva in the oral cavity. It is wrapped around the ramus of the mandible in humans and may be an unintentional target in RT for HNC. Inflammation of the parotid gland has been demonstrated to induce xerostomia resulting in dryness of the oral cavity (Dirix & Nuyts, 2010; Mortazavi et al., 2014). Of note, radiation-induced xerostomia is the most frequently reported complications of RT for HNC and significantly affects patients’ quality of life (Langendijk et al., 2008).

Traditional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) have been used for staging and monitoring structural changes. In contrast, positron emission tomography (PET) is frequently used to visualize physiological and molecular changes (Buchbender et al., 2012). 18F-fluorodeoxyglucose (FDG) is the most commonly used tracer for PET scanning. It is a radiolabeled glucose analog, taken up by cells that rapidly consume and metabolize glucose, such as cancer and inflammatory cells (Love et al., 2005; Rege et al., 1993; Fletcher et al., 2008). The fused FDG-PET/CT allows for detection and quantification of glucose metabolism on the molecular level leading to a more accurate detection of malignancies and inflammatory changes in the head and neck (Beichel et al., 2019; Castaldi et al., 2013). Much of the existing literature on the clinical application of FDG has focused on the radiotracer’s utility in diagnosing malignancies due to the typically increased glucose metabolism of cancer cells, but FDG has also been used for decades to detect inflammatory processes (Borja et al., 2020a). Therefore, we predict that FDG-PET/CT will show potential in the evaluation of radiation-induced inflammation in the parotid gland that predisposes patients to xerostomia. The aim of the present study is to demonstrate the feasibility of FDG-PET/CT in the detection and quantification of the inflammatory effect of RT on the parotid gland in HNC patients.

Methods

Patient population

Between February 9, 2010 and November 27, 2018, 64 patients with HNC were treated with photon, proton, or combined photon/proton RT, in addition to chemotherapy with either cisplatin or cetuximab at the University of Pennsylvania. All patients were imaged pre- and 3 months post-treatment with FDG-PET/CT. Of the 64 patients, 17 were not included in the study due to technical issues associated with their FDG-PET/CT scans, inferior imaging quality in the head and neck region and/or mismatch between PET and CT images. The collected clinical data included age, sex, and primary tumor location. The primary tumor locations were tongue, larynx, oropharynx, nasopharynx, and hypopharynx. PET/CT scans used for the study were free from background noise, scatter, and metal artifacts. The study was approved by the Institutional Review Board. It was conducted in compliance with the Health Insurance Portability and Accountability Act (HIPAA).

FDG-PET/CT image acquisition

All subjects were injected intravenously with 5.0 MBq/kg FDG. After approximately 60 min, FDG-PET/CT images were obtained using the same standardized protocol. Imaging was performed on hybrid PET/CT scanners with comparable spatial resolution (Siemens Biograph 64 mCT (Siemens Healthineers AG, Chicago, IL, USA) and Philips Gemini TF 16 (Philips Medical Systems, Andover, MA, USA)). The images were acquired in accordance with international guidelines (Delbeke et al., 2006; Boellaard et al., 2015) and the institutional PET/CT protocol, including quality control, calibration, and harmonization of PET/CT scanners and validation of standardized uptake value (SUV) measurements. Patients fasted for at least 6 h prior to scanning, and serum glucose levels were immediately measured prior to FDG injection. Three acquisition protocols were used: one for body mass index (BMI) under 30, another for BMI between 30 and 35, and the third BMI over 35; the CT settings were 50, 100, and 150 mAs, respectively, and all at 120 kVp. For the PET acquisitions, the time per bed was 1.5, 2, and 3 min, respectively. Low-dose CT imaging was performed for anatomic localization and attenuation correction. PET images were corrected for scattering, attenuation, scanner dead time, and random coincidences.

FDG-PET/CT image analysis

FDG-PET/CT scans were analyzed using the OsiriX MD software v.10.0.2 (DICOM viewer and image-analysis program, Pixmeo SARL; Bernex, Switzerland). Sequential axial PET/CT slices were used to draw regions of interest (ROI) manually around the right and left parotid glands using a closed polygon (Fig. 1). The reader was blinded to the paired PET scans (pre- and post-treatment scans). Parotid gland ROIs were drawn beginning superiorly at the level of condyle down to the angle of the mandible inferiorly. The skin and external ear were defined as the lateral borders, the styloid process of the temporal bone was the medial border, and the mastoid process of the temporal bone was the posterior border.

Fig. 1
figure 1

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) images of the parotid gland. Left: Fused FDG PET/CT, right: CT. The delineation of the region of interest (ROI) is highlighted for the right and left parotid glands

Full size image

The SUVmean was calculated as the average value of all voxels in the ROI. To determine the global activity of the parotid gland, the SUVmean as well as area (mm2) of each ROI at each transverse slice was measured and recorded. The SUVmean was multiplied by the area, and the products were summed, the result of which was divided by the sum of the total area of the ROIs (Sum (SUVmean×Area))/(Sum Area). This resulted in the average SUVmean (Avg SUVmean) representative of a global inflammation burden of the parotid gland. The SUVmax was defined as the hottest voxel within the ROI. The average SUVmax (Avg SUVmax) represented the average value from all trans-axial slices, which included both right and left parotid glands. Statistical comparison was completed by using the Avg SUVmean and Avg SUVmax of all slices.

Statistical analysis

For each subject, pre- and post-treatment Avg SUVmean and Avg SUVmax were calculated. A two-tailed paired t test in the STATA software (Stata/IC Version 10.1, StataCorp, College Station, TX) was used to compare the Avg SUVmean and Avg SUVmax in the pre- and post-treatment scans. The level of significance was defined as a p value of less than 0.05. The average mean increases in SUVmean and SUVmax were calculated by subtracting pre-treatment from post-treatment Avg SUVmean and Avg SUVmax values for each patient.

Results

The data collected from a total of 47 HNC patients (25 males, 22 females), mean age 59.7 years (range 42-78) with pre and post-treatment FDG-PET/CT were included. Thirty-three patients were in the photon RT group, while seven patients were in each of the proton RT and combined photon/proton RT groups. Primary tumor location, age, gender, and race are summarized in Table 1.

Table 1 Primary tumor location, age, gender, and race
Full size table

Statistical data are summarized in Tables 2 and 3. The parotid gland Avg SUVmean in patients treated with photon RT was significantly higher in post-treatment scans (1.50, p < 0.05) relative to those done pre-treatment (1.38, p < 0.05) (Fig. 2). The Avg SUVmax was higher in post-treatment scans (2.06) compared to those done pre-treatment (1.96), but the difference was not statistically significant.

Table 2 Parotid gland average mean standardized uptake values (Avg SUVmean) in pre- and post- treatment scans of head-and-neck cancer patients
Full size table
Table 3 Parotid gland average maximum standardized uptake values (Avg SUVmean) in pre- and post- treatment scans of head-and-neck cancer patients
Full size table
Fig. 2
figure 2

Changes in average standardized uptake value mean (Avg SUVmean) of the parotid gland before and 3 months after treatment in patients treated with photon RT

Full size image

In patients treated with proton RT, the parotid gland Avg SUVmean was not significantly different in post-treatment scans (1.32, p > 0.05) when compared to pre-treatment scans (1.25, p > 0.05) (Fig. 3). Evaluation of pre- and post-treatment scans for Avg SUVmax yielded a similar finding (post-treatment [1.73, p > 0.05] and pre-treatment [1.72, p > 0.05]).

Fig. 3
figure 3

Changes in average standardized uptake value mean (Avg SUVmean) of the parotid gland before and 3 months after treatment in patients treated with proton RT

Full size image

Analysis of the parotid gland Avg SUVmean in patients treated with combined photon/proton RT was not significantly different in post-treatment scans (1.32, p > 0.05) when compared to pre-treatment scans (1.25, p > 0.05) (Fig. 4). Similar findings were presented for Avg SUVmax (post-treatment [2.12, p > 0.05] and pre-treatment [1.90, p > 0.05]).

Fig. 4
figure 4

Changes in average standardized uptake value mean (Avg SUVmean) of the parotid gland before and 3 months after treatment in patients treated with combined photon/proton RT

Full size image

Discussion

Our study demonstrates a significant increase in FDG uptake in the parotid glands of HNC patients following photon RT and chemotherapy treatments. Investigating the impact of these treatments on the parotid gland is critical, not only because of its role in saliva production but also due to the fact that cranial nerve VII (facial nerve) lies in close proximity to and innervates the gland. This nerve also innervates numerous muscles of facial expression, as well as the stylohyoid and posterior belly of the digastric muscles, which play a critical role in swallowing (Dulak & Naqvi, 2019). The glossopharyngeal nerve provides parasympathetic innervation to the parotid gland, as well as sensory innervation to the posterior one-third of the tongue and pharynx. Photon RT and/or chemotherapy-induced damage of the parotid gland can impact glossopharyngeal nerve function and indirectly lead to deleterious effects on adjacent structures in the head and neck region (García Santos et al., 2018). Thus, determining the FDG uptake in the parotid gland is of clinical importance in investigating potential previously underappreciated side effects of radiotherapy in HNC cancer patients.

In our study, we found that Avg SUVmean was significantly higher in the parotid gland following photon RT, but not in patients who underwent proton RT or combined proton/photon RT. Although Avg SUVmean was significantly increased in patients receiving photon RT, SUVmax values were not significantly different in pre-treatment versus post-treatment scans of patients receiving any form of RT. SUVmax is the maximum voxel value of SUV in the target structure/ROI. SUVmax is simple and observer independent; hence, SUVmax is the most commonly used parameter in clinical practice. However, SUVmax does not represent an entire structure’s metabolic burden because the value is from only one voxel. Furthermore, SUVmax is sensitive to image noise, and is therefore impacted by various patient characteristics and imaging parameters. On the other hand, Avg SUVmean accounts for all uptake within the ROIs and is more reflective of the total pathological changes in glucose metabolism, which suggests that Avg SUVmean is a more accurate value to use in this data collection. Since we suspect that radiation-induced parotid injury is a diffuse pathology that has the potential to elicit an inflammatory response across the entire gland, we used the Avg SUVmean, as it is likely to be a more accurate indicator of the extent of the global inflammation (Høilund-Carlsen et al., 2019; Borja et al., 2020b).

There are several artifacts encountered in PET/CT imaging including attenuation correction artifacts commonly associated with the use of CT. Attenuation correction algorithms work well for most applications in the majority of patients. However, these algorithms tend to overcorrect objects that have higher density but are not true bone pixels. Dental implants or fillings can cause such an attenuation correction artifact and can confound image interpretation and affect the quantification in the head and neck region. In the present study, of the 64 patients, 17 were not included in the study due to technical issues including the presence of artifacts related to metallic based restorations, orthodontic appliances, and other dental procedures, which are the main cause of beam hardening. This confirms the lack of beam hardening artifact effect on our measurements.

We assert that the increased FDG uptake observed in this study was a result of RT-induced inflammation in the parotid gland. Cellular uptake of FDG is a marker for inflammation, and these results confirm its utility in identifying parotid gland pathology following RT in HNC patients. In classic parotitis, this inflammation is most often the result of a localized infection or cellular damage, though the irritation can be caused by a myriad of factors, including pathogenic microbes derived from the oral cavity, metabolic imbalances, and autoimmune disorders (Patel et al., 2017). Initiation of inflammatory processes in the gland can lead to a decrease in salivary production, causing dehydration of the gland as well as a distortion of the parotid duct and metaplasia of the ductal epithelium (Chitre & Premchandra, 1997). Uptake of FDG may begin to increase subsequent to the preliminary irritation and continue to increase as the inflammatory response progresses (Chitre & Premchandra, 1997). Since RT has been shown to increase systemic inflammation, patients experience a significant risk in the perturbation of the parotid gland, since it is particularly susceptible to irritation (Brook, 1992; Schaue et al., 2015).

It is critical to acknowledge the limitations of our study. This was a retrospective analysis with a relatively small sample size of patients. Thus, future evaluation of the use of FDG-PET/CT as a surrogate measurement of inflammatory activity in the parotid gland after RT treatment should be directed toward prospective studies using large numbers of patients. Information regarding full tumor stage, type of radiation field, the exact dosage of radiotherapy administered to patients, and oral complications were not available for the current study, which limited the description of our patient cohort. A survey reported that 64% of at least 3 years survivors after RT suffered from moderate to severe xerostomia (Wijers et al., 2002). Thus, future studies must include detailed information regarding the occurrence of xerostomia in order to determine whether increased parotid-uptake of FDG can be used to predict the onset of this condition. The partial volume effect, which accounts for signal overlap from neighboring anatomical structures and potential movement of the patients during scan acquisition, may have altered the data used in these analyses. Therefore, the regions used as borders in determining the extent of the ROIs may have been ambiguous, depending on the quality of the scan. The influence of partial volume effect is due to the limited resolution of the technology used in obtaining these scans (Cysouw et al., 2016; Soret et al., 2007). This could account for the single outlier observed in the data, which might have introduced further uncertainty into the results (Fig. 2). In addition, because the patients who participated in the study received both chemotherapy and photon RT, it is not possible to differentiate between the inflammatory effects of each treatment individually. Finally, there were only two-time points assessed in this study, pre-treatment and 3 months post-treatment, which prevented the evaluation of FDG uptake throughout the entire post-treatment period.

The present study suggests that an increase beyond normal physiological glucose uptake in the parotid gland occurs as a manifestation of RT-induced inflammation. Given that inflammation is followed by cell damage and fibrosis of some of the glandular tissue (Wynn & Ramalingam, 2012), we predict that additional follow-up scans will demonstrate a decrease in the parotid gland uptake due to lack of normal gland activity and function. It would be helpful to direct future studies toward more longitudinal assessments of FDG uptake in the parotid gland to better track changes in signaling over time to determine the time frame of cell damage and fibrosis manifesting as a decline in parotid gland function compared to pre-treatment.

Protocols utilizing photon beams are currently the most common form of RT for HNC, while less than 1% of patients are treated with proton therapy (Mohan & Grosshans, 2017). When comparing proton to photon therapy, proton therapy reveals an added advantage of lower dose and smaller number of beams (Levin et al., 2005). In the present study, no significant differences were found between pre- and post-treatment parotid FDG uptake in patients treated with proton RT. This observation might be indicative of there being less radiation delivered to normal tissues in close proximity to actual tumors, thereby minimizing collateral toxicity and limiting the extent of side effects traditionally associated with photon-based RT (Mohan & Grosshans, 2017; Lin, 2012). Considering the small patient population receiving only proton therapy, the result must be interpreted with caution and should be confirmed in further studies.

The present study demonstrated significantly higher FDG uptake in the parotid glands of patients undergoing photon-based RT for treatment of HNC. This increase in glucose metabolism may be indicative of radiation-induced inflammation, which subsequently can progress result in decreased functionality of the parotid gland. Future studies should include a larger sample to allow comparison of the effect of photon RT for treatment of HNC to other modalities of RT in order to assess the differential impact on parotid gland function. Confirmation of the correlation between FDG uptake and saliva production might enable clinicians to choose alternative RT regimens and/or intervene at an earlier stage and prevent the sequela of xerostomia.

Conclusion

FDG-PET/CT has the potential to be used to measure the metabolic activity associated with RT-induced inflammation and predict parotid gland dysfunction.

Availability of data and materials

All data generated or analyzed during this study are included in this article [and its supplementary information files].

Abbreviations

FDG-PET/CT:

18F-fluorodeoxyglucose-positron emission tomography/computed tomography

RT:

Radiotherapy

HNC:

Head and neck cancer

CT:

Computed tomography

MRI:

Magnetic resonance imaging

PET:

Positron emission tomography

FDG:

18F-fluorodeoxyglucose

HIPAA:

Health Insurance Portability and Accountability Act

SUV:

Standardized uptake value

Avg SUVmean:

Average mean standardized uptake value

Avg SUVmax:

Average maximum standardized uptake value

ROI:

Region of interest

BMI:

Body mass index

References

  1. Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA (2019) Modern radiotherapy for head and neck cancer. Semin Oncol 46:233–245 https://doi.org/10.1053/j.seminoncol.2019.07.002

    CAS  Article  Google Scholar 

  2. Beichel RR, Ulrich EJ, Smith BJ, Bauer C, Brown B, Casavant T et al (2019) FDG PET based prediction of response in head and neck cancer treatment: assessment of new quantitative imaging features. PLoS ONE 14 https://doi.org/10.1371/journal.pone.0215465

  3. Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354 https://doi.org/10.1007/s00259-014-2961-x

    CAS  Article  Google Scholar 

  4. Borja AJ, Hancin EC, Dreyfuss AD, Zhang V, Mathew T, Rojulpote C et al (2020a) 18F-FDG-PET/CT in the quantification of photon radiation therapy-induced vasculitis. Am J Nucl Med Mol Imaging 10:66–73

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Borja AJ, Hancin EC, Zhang V, Revheim M-E, Alavi A (2020b) Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders. Eur J Nucl Med Mol Imaging https://doi.org/10.1007/s00259-020-04697-y

  6. Brook I (1992) Diagnosis and management of parotitis. Arch Otolaryngol Neck Surg 118:469–471 https://doi.org/10.1001/archotol.1992.01880050015002

    CAS  Article  Google Scholar 

  7. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G (2012) Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med Off Publ Soc Nucl Med 53:928–938 https://doi.org/10.2967/jnumed.112.105338

    Google Scholar 

  8. Castaldi P, Leccisotti L, Bussu F, Miccichè F, Rufini V (2013) Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-Facc 33:1–8

    CAS  Google Scholar 

  9. Chen S-C (2019) Oral dysfunction in patients with head and neck cancer: a systematic review. J Nurs Res JNR 27:e58 https://doi.org/10.1097/jnr.0000000000000363

    Article  Google Scholar 

  10. Chitre VV, Premchandra DJ (1997) Recurrent parotitis. Arch Dis Child 77:359–363 https://doi.org/10.1136/adc.77.4.359

    CAS  Article  Google Scholar 

  11. Chrapko BE, Chrapko M, Nocuń A, Stefaniak B, Zubilewicz T, Drop A (2016) Role of 18F-FDG PET/CT in the diagnosis of inflammatory and infectious vascular disease. Nucl Med Rev 19:28–36 https://doi.org/10.5603/NMR.2016.0006

    Article  Google Scholar 

  12. Cysouw MCF, Kramer GM, Hoekstra OS, Frings V, de Langen AJ, Smit EF et al (2016) Accuracy and precision of partial-volume correction in oncological PET/CT studies. J Nucl Med Off Publ Soc Nucl Med 57:1642–1649 https://doi.org/10.2967/jnumed.116.173831

    Google Scholar 

  13. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47:885–95.

  14. Dirix P, Nuyts S (2010) Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol 11:85–91 https://doi.org/10.1016/S1470-2045(09)70231-1

    Article  Google Scholar 

  15. Dulak D, Naqvi IA (2019) Neuroanatomy, Cranial Nerve 7 (Facial). StatPearls Publishing, StatPearls, Treasure Island (FL)

    Google Scholar 

  16. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508 https://doi.org/10.2967/jnumed.107.047787

    Article  Google Scholar 

  17. García Santos JM, Sánchez Jiménez S, Tovar Pérez M, Moreno Cascales M, Lailhacar Marty J, Fernández-Villacañas Marín MA (2018) Tracking the glossopharyngeal nerve pathway through anatomical references in cross-sectional imaging techniques: a pictorial review. Insights Imaging 9:559–569 https://doi.org/10.1007/s13244-018-0630-5

    Article  Google Scholar 

  18. Giuranno L, Ient J, De Ruysscher D, Vooijs MA (2019) Radiation-induced lung injury (RILI). Front Oncol 9:877 https://doi.org/10.3389/fonc.2019.00877

    Article  Google Scholar 

  19. Head and Neck Cancer - Statistics. CancerNet 2012. https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics (accessed November 9, 2019).

  20. Høilund-Carlsen PF, Edenbrandt L, Alavi A (2019) Global disease score (GDS) is the name of the game! Eur J Nucl Med Mol Imaging 46:1768–1772

    Article  Google Scholar 

  21. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ (2008) Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol 26:3770–3776 https://doi.org/10.1200/JCO.2007.14.6647

    Article  Google Scholar 

  22. Levin WP, Kooy H, Loeffler JS, DeLaney TF (2005) Proton beam therapy. Br J Cancer 93:849–854 https://doi.org/10.1038/sj.bjc.6602754

    CAS  Article  Google Scholar 

  23. Lin A, Swisher-McClure S, Millar LB, Kirk M, Yeager C, Kassaee A, et al. Proton therapy for head and neck cancer: current applications and future directions. Transl Cancer Res 2012;1:255-263–263. https://doi.org/10.21037/786.

  24. Love C, Tomas MB, Tronco GG, Palestro CJ (2005) FDG PET of infection and inflammation. RadioGraphics 25:1357–1368 https://doi.org/10.1148/rg.255045122

    Article  Google Scholar 

  25. Mohan R, Grosshans D (2017) Proton therapy - present and future. Adv Drug Deliv Rev 109:26–44 https://doi.org/10.1016/j.addr.2016.11.006

    CAS  Article  Google Scholar 

  26. Mortazavi H, Baharvand M, Movahhedian A, Mohammadi M, Khodadoustan A (2014) Xerostomia due to systemic disease: a review of 20 conditions and mechanisms. Ann Med Health Sci Res 4:503–510 https://doi.org/10.4103/2141-9248.139284

    CAS  Article  Google Scholar 

  27. Patel P, Scott S, Cunningham S (2017) Challenging case of parotitis: a comprehensive approach. J Am Osteopath Assoc 117:e137–e140 https://doi.org/10.7556/jaoa.2017.152

    Article  Google Scholar 

  28. Rege SD, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y et al (1993) Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 189:807–812 https://doi.org/10.1148/radiology.189.3.8234708

    CAS  Article  Google Scholar 

  29. Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH (2015) Radiation & inflammation. Semin Radiat Oncol 25:4–10 https://doi.org/10.1016/j.semradonc.2014.07.007

    Article  Google Scholar 

  30. Shunmuga Sundaram C, Dhillon HM, Butow PN, Sundaresan P, Rutherford C (2019) A systematic review of body image measures for people diagnosed with head and neck cancer (HNC). Support Care Cancer 27:3657–3666 https://doi.org/10.1007/s00520-019-04919-6

    Article  Google Scholar 

  31. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932–945

    Article  Google Scholar 

  32. Wijers OB, Levendag PC, Braaksma MMJ, Boonzaaijer M, Visch LL, Schmitz PIM (2002) Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 24:737–747 https://doi.org/10.1002/hed.10129

    Article  Google Scholar 

  33. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040 https://doi.org/10.1038/nm.2807

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Affiliations

  1. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA

    Alaa Mouminah, Austin J. Borja, Emily C. Hancin, Thomas J. Werner, Abass Alavi & Mona-Elisabeth Revheim

  2. The University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA

    Alaa Mouminah, Yu Cheng Chang & Jonathan Korostoff

  3. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Austin J. Borja

  4. Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA

    Emily C. Hancin

  5. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

    Samuel Swisher-McClure

  6. Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

    Mona-Elisabeth Revheim

  7. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

    Mona-Elisabeth Revheim

Authors
  1. Alaa Mouminah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Austin J. Borja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily C. Hancin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Cheng Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas J. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samuel Swisher-McClure
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jonathan Korostoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abass Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mona-Elisabeth Revheim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: AA, MER. Data curation: AM, AJB, AA, and TJW. Formal analysis: AM, AJB, TJW, and Investigation: AM, AJB, MER. Methodology: AA, MER. Resources: AM, AJB, ECH, TJW, YCC, SSM, JK, AA, and MER. Supervision: AA, MER. Visualization: AM, AJB, ECH, and TJW. Writing–Original draft preparation: AM, AJB, ECH, and MER. Writing—review and editing: AM, AJB, ECH, TW, YCC, SSM, JK, AA, and MER. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mona-Elisabeth Revheim.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board. It was conducted in compliance with the Health Insurance Portability and Accountability Act (HIPAA).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mouminah, A., Borja, A.J., Hancin, E.C. et al. 18F-FDG-PET/CT in radiation therapy-induced parotid gland inflammation. European J Hybrid Imaging 4, 22 (2020). https://doi.org/10.1186/s41824-020-00091-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41824-020-00091-x

Keywords

  • PET/CT
  • 18F-FDG
  • Radiation therapy
  • Parotid gland
  • Parotid gland inflammation
  • Head and neck cancer